3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
4
Leukemia, Hairy Cell
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Thyroid Carcinoma, Anaplastic
2
Skin Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid cancer, follicular
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Interventions
Cyclophosphamide
31
fludarabine
28
Whole-Body Irradiation
18
Mycophenolic Acid
18
venetoclax
14
Tacrolimus
14
fludarabine phosphate
13
Standard of Care
13
Specimen Handling
10
Practice Guidelines as Topic
10
Melphalan
10
Busulfan
10
Sirolimus
9
Thiotepa
8
Interviews as Topic
8
Azacitidine
8
Educational Status
7
trametinib
6
Surveys and Questionnaires
6
Methods
6
Mesna
6
Biopsy
6
thymoglobulin
5
Rituximab
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Early Intervention, Educational
5
Behavior Therapy
5
Antilymphocyte Serum
5
Peripheral Blood Stem Cell Transplantation
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Vemurafenib
×
1 year
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled